Notice type: 3rd Party Publications
Date: 05/06/2018
Please find below the links to all Direct Healthcare Professional Communications (DHPCs) issued in May 2018
Granulocyte colony-stimulating factors (G-CSFs) (Filgrastim, Lenograstim, Lipegfilgrastim and Pegfilgrastim) - Important Safety Information from Amgen Europe B.V, Chugai Pharma UK, Teva, Apotex Europe B.V, and Accord Healthcare Ltd as approved by the HPRA
Xgeva (denosumab) - Important Safety Information from Amgen as approved by the HPRA (May 2018)
Tivicay (dolutegravir), Triumeq (dolutegravir, abacavir, lamivudine), Juluca (dolutegravir, rilpivirine) - Important Safety Information from Viiv Healthcare as approved by the HPRA